Skip to content
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Neurology

How to Find an NF1 Specialist for Adults

At a Glance

To find an NF1 specialist, look for a multidisciplinary clinic through directories like the Children's Tumor Foundation. When evaluating a doctor, especially for adult care, ask about their adult patient volume, care coordination team, and experience with treatments like MEK inhibitors.

Finding a doctor who truly understands Neurofibromatosis type 1 (NF1)—especially for adults—can be challenging but is crucial for managing the condition proactively. You will want to look for a multidisciplinary NF clinic, consult directories from patient advocacy organizations, ask specific questions about their volume of adult patients, and ensure they have experience with newer targeted therapies like MEK inhibitors.

Why You Need a Multidisciplinary NF Clinic

Because NF1 is a complex condition that can affect many different systems in the body, seeing a single general practitioner is rarely enough. While a primary care doctor can manage many everyday health needs, coordination with a specialized NF1 clinic is strongly recommended [1][2]. A multidisciplinary team (a group of healthcare professionals from different specialties) usually includes neurologists, geneticists, oncologists, surgeons, and pain management specialists working together [2][3]. This team approach is essential for managing serious or complex NF1 issues, such as monitoring for specific cancers, handling vascular complications, or navigating a high-risk pregnancy [3][4][5].

How to Find a Clinic

The best place to start your search is through established patient advocacy groups. In the United States, the Children’s Tumor Foundation (CTF) maintains an NF Clinic Network directory [6]. This network is designed to help patients find specialized care centers that meet specific standards for treating NF1 and all forms of schwannomatosis, including NF2-related schwannomatosis [6]. For international patients, looking for regional equivalents like European Reference Networks (ERNs) can be a helpful starting point.

Keep in mind that geographic access to specialized NF care is often more limited for adults than for children [6]. You may need to travel further to find a high-volume center that focuses on adult care [6]. If regular travel is not an option for you, ask if a specialist can co-manage your care alongside your local primary care doctor, or if they offer telehealth appointments for routine follow-ups.

Questions to Evaluate a Specialist or Center

When you contact a potential specialist or clinic, it is important to ask questions to determine if they are the right fit for your needs:

  • “How many adult NF1 patients do you treat?” Adult-focused care must address different risks than pediatric care, such as breast cancer surveillance and vascular complications [7][8]. Make sure the clinic has a structured approach to monitoring for adult-onset issues [9]. This includes rare but important things to monitor for, like pheochromocytomas (rare tumors of the adrenal gland that can cause high blood pressure) or soft-tissue sarcomas (specifically Malignant Peripheral Nerve Sheath Tumors, or MPNSTs, which are cancerous tumors that can develop in nerve sheaths) [10][3].
  • “What medical specialties are part of your core team?” Ensure they have a multidisciplinary approach to coordinate your care holistically [1][2].
  • “Do you have a dedicated nurse navigator or clinic coordinator?” Managing appointments across multiple specialties can be overwhelming, and a dedicated coordinator often makes the biggest difference in your experience.
  • “Are you experienced in prescribing and monitoring MEK inhibitors?” This is a critical question, as targeted therapies (daily pills that block tumor growth pathways) are changing how NF1 is treated. For example, a MEK inhibitor called mirdametinib is now an FDA-approved therapy for adults with symptomatic, inoperable plexiform neurofibromas (complex nerve tumors that cannot be safely removed with surgery) [11][12]. Trials have demonstrated this drug can provide significant tumor shrinkage and improvements in pain and quality of life [12]. While another MEK inhibitor, selumetinib, is FDA-approved for children, trials continue to evaluate its use in adults [13][14]. Your specialist should be comfortable navigating these treatments and managing their potential side effects [15].
  • “Are you involved in clinical trials?” Clinics connected to research networks often have the most up-to-date knowledge on emerging therapies and surveillance guidelines [16][17].

Transitioning from Pediatric Care

If you or your child are moving from a pediatric NF clinic to adult care, this transition requires careful planning, which should ideally begin in early adolescence around age 13 or 14 [18]. Young adults often need extra support to develop self-management skills as they take charge of their own healthcare [19][20]. Structured transition programs can help bridge the gap, ensuring that long-term health monitoring continues without interruption [18].

For Newly Diagnosed Adults

If you were diagnosed with NF1 in adulthood, you might not have the foundation of pediatric specialty care to build upon. This makes it even more critical to establish a baseline with a dedicated adult NF specialist. They can review your complete medical history, ensure you receive baseline imaging (such as whole-body MRIs to map any existing tumors), and set up a surveillance schedule tailored to your age and symptoms [21][9].

Common questions in this guide

Why do I need a multidisciplinary clinic for NF1?
NF1 affects many systems in the body, so a single doctor is rarely enough. A multidisciplinary clinic brings together neurologists, geneticists, oncologists, and other specialists to proactively manage complex issues and coordinate your long-term care.
Where can I find an NF1 specialist?
A great starting point is the NF Clinic Network directory maintained by the Children's Tumor Foundation. This network helps patients find specialized centers that meet specific standards for treating all forms of neurofibromatosis.
What questions should I ask a new NF1 specialist?
You should ask how many adult NF1 patients they treat and if they have experience prescribing newer targeted therapies like MEK inhibitors. It is also highly recommended to ask if they have a dedicated nurse navigator to help coordinate your care.
Can my local doctor help manage my NF1 if I can't travel?
Yes, if regular travel to a specialized clinic is difficult, you can ask an NF specialist to co-manage your care with your local primary care doctor. Many specialized centers also offer telehealth appointments for routine follow-ups.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific screening tests and imaging should I be getting at my age, and how often?
  2. 2.How many adult patients with NF1 do you currently manage, and what specialties make up your multidisciplinary team?
  3. 3.What is your experience with prescribing FDA-approved MEK inhibitors like mirdametinib for adults, and how do you monitor for potential side effects?
  4. 4.Are you willing to coordinate care with my local primary care physician if I cannot travel to your clinic frequently?
  5. 5.Do you have a clinic coordinator or nurse navigator to help manage my appointments and care plan?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

    Stewart DR, Korf BR, Nathanson KL, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2018; (20(7)):671-682 doi:10.1038/gim.2018.28.

    PMID: 30006586
  2. 2

    Plexiform Neurofibroma: A Case Report.

    Bang K, Shenoi R, Waghchoure AV

    Cureus 2024; (16(7)):e65747 doi:10.7759/cureus.65747.

    PMID: 39211690
  3. 3

    Uncommon Thigh Mass in Neurofibromatosis Type 1: Unveiling Aggressive Epithelioid Sarcoma.

    Gharbi MA, Limaiem F, Romdhane KB, et al.

    European journal of case reports in internal medicine 2024; (11(4)):004432 doi:10.12890/2024_004432.

    PMID: 38584901
  4. 4

    Maternal and Fetal Complications in Pregnant Women with Neurofibromatosis Type 1: Literature Review and Two Case Reports.

    Nastac A, Panaitescu AM, Huluță I, et al.

    Journal of clinical medicine 2025; (14(2)) doi:10.3390/jcm14020451.

    PMID: 39860457
  5. 5

    [Emergency management and perioperative strategies for intra-tumoral hemorrhage in neurofibromatosis type 1-related giant plexiform neurofibroma].

    Zhu B, Xiao Y, Liao R, et al.

    Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery 2024; (38(10)):1180-1185 doi:10.7507/1002-1892.202406074.

    PMID: 39433490
  6. 6

    Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.

    Merker VL, Dai A, Radtke HB, et al.

    BMC health services research 2018; (18(1)):668 doi:10.1186/s12913-018-3471-5.

    PMID: 30157837
  7. 7

    Gastrointestinal stromal tumor in patient with neurofibromatosis type 1: A case report.

    Ibrahimi A, Lachkar S, Boualaoui I, et al.

    International journal of surgery case reports 2025; (129()):111166 doi:10.1016/j.ijscr.2025.111166.

    PMID: 40106943
  8. 8

    [Rupture of Intercostal Aneurysm Associated with von Recklinghausen's Disease:Report of a Case].

    Sakamoto S, Kurumisawa S, Akutsu H, et al.

    Kyobu geka. The Japanese journal of thoracic surgery 2026; (79(2)):144-147.

    PMID: 42098017
  9. 9

    Diagnostic and follow-up protocol for adult patients with neurofibromatosis type 1 in a Spanish reference unit.

    Solares I, Vinal D, Morales-Conejo M

    Revista clinica espanola 2022; (222(8)):486-495 doi:10.1016/j.rceng.2022.02.007.

    PMID: 35688675
  10. 10

    An Autopsy Case of Sudden Death in Neurofibromatosis Type 1 With Pheochromocytoma and Myocarditis.

    Takamiya M, Niitsu H, Saigusa K

    The American journal of forensic medicine and pathology 2018; (39(1)):78-81 doi:10.1097/PAF.0000000000000367.

    PMID: 29210711
  11. 11

    Targeted Therapies in Neurofibromatosis Type 1.

    Sato AA, Earl D, Wallace SE

    American journal of medical genetics. Part C, Seminars in medical genetics 2025; (199(3)):154-160 doi:10.1002/ajmg.c.32151.

    PMID: 40968507
  12. 12

    ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.

    Moertel CL, Hirbe AC, Shuhaiber HH, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(6)):716-729 doi:10.1200/JCO.24.01034.

    PMID: 39514826
  13. 13

    FDA Approval Summary: Selumetinib for Plexiform Neurofibroma.

    Casey D, Demko S, Sinha A, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2021; (27(15)):4142-4146 doi:10.1158/1078-0432.CCR-20-5032.

    PMID: 33712511
  14. 14

    Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma.

    Kim H, Yoon HM, Kim EK, et al.

    Neuro-oncology 2024; (26(12)):2352-2363 doi:10.1093/neuonc/noae121.

    PMID: 38975694
  15. 15

    The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.

    Klesse LJ, Jordan JT, Radtke HB, et al.

    The oncologist 2020; (25(7)):e1109-e1116 doi:10.1634/theoncologist.2020-0069.

    PMID: 32272491
  16. 16

    Neurofibromatosis type 1.

    Cimino PJ, Gutmann DH

    Handbook of clinical neurology 2018; (148()):799-811 doi:10.1016/B978-0-444-64076-5.00051-X.

    PMID: 29478615
  17. 17

    Impact of trametinib on the neuropsychological profile of NF1 patients.

    Lalancette E, Cantin É, Routhier MÈ, et al.

    Journal of neuro-oncology 2024; (167(3)):447-454 doi:10.1007/s11060-024-04624-3.

    PMID: 38443693
  18. 18

    Neurofibromatosis Type 1 (NF1): Addressing the Transition from Pediatric to Adult Care.

    Radtke HB, Berger A, Skelton T, Goetsch Weisman A

    Pediatric health, medicine and therapeutics 2023; (14()):19-32 doi:10.2147/PHMT.S362679.

    PMID: 36798587
  19. 19

    Perceived transition readiness among adolescents and young adults with neurofibromatosis type 1 and plexiform neurofibromas: a cross-sectional descriptive study.

    Siegel A, Lockridge R, Struemph KL, et al.

    Journal of pediatric psychology 2024; (49(6)):383-391 doi:10.1093/jpepsy/jsae006.

    PMID: 38366576
  20. 20

    Transition to adult care of young patients with neurofibromatosis type 1 and cognitive deficits: a single-centre study.

    Lausdahl S, Handrup MM, Rubak SL, et al.

    Orphanet journal of rare diseases 2022; (17(1)):208 doi:10.1186/s13023-022-02356-z.

    PMID: 35597953
  21. 21

    Clinical Value of Multiparametric Whole-Body Magnetic Resonance Imaging over Whole-Spine Magnetic Resonance Imaging in Patients with Neurofibromatosis Type I.

    Zhang L, Dessouky R, Xi Y, et al.

    World neurosurgery 2017; (108()):729-737 doi:10.1016/j.wneu.2017.09.066.

    PMID: 28939538

This page provides guidance on finding an NF1 specialist for informational purposes only and does not replace professional medical advice. Always consult a healthcare provider for recommendations specific to your condition.

Get notified when new evidence is published on Neurofibromatosis type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.